United Therapeutics (UTHR) Cash & Equivalents (2009 - 2026)
United Therapeutics (UTHR) posted Cash & Equivalents of $1.3 billion for Q1 2026, down 17.82% sequentially from $1.6 billion in Q4 2025, and down 32.64% YoY from $1.9 billion in Q1 2025.
United Therapeutics (UTHR) Cash & Equivalents (2009 - 2026) Analysis & Trends
United Therapeutics has reported Cash & Equivalents for 18 years, with the latest figure at $1.3 billion in Q1 2026.
- Quarterly Cash & Equivalents fell 32.64% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 32.64% YoY) and the FY2025 annual result came in at $1.6 billion, down 8.25% from the prior year.
- Cash & Equivalents fell to $1.3 billion in Q1 2026 per UTHR's latest filing, from $1.6 billion in the prior quarter.
- Over five years, Cash & Equivalents peaked at $1.9 billion in Q1 2025 and troughed at $795.2 million in Q2 2022.
- A 5-year average of $1.3 billion and a median of $1.3 billion in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 51.81% in 2025, then slumped 32.64% in 2026.
- Over 5 years, Cash & Equivalents stood at $961.2 million in 2022, then increased by 25.65% to $1.2 billion in 2023, then surged by 40.53% to $1.7 billion in 2024, then fell by 8.25% to $1.6 billion in 2025, then declined by 17.82% to $1.3 billion in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $1.3 billion, $1.6 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.80 Bn |
| Mar 31, 2026 | 1.28 Bn |
| Dec 31, 2025 | 1.56 Bn |
| Sep 30, 2025 | 1.34 Bn |
| Jun 30, 2025 | 1.59 Bn |
| Mar 31, 2025 | 1.90 Bn |
| Dec 31, 2024 | 1.70 Bn |
| Sep 30, 2024 | 1.55 Bn |
| Jun 30, 2024 | 1.36 Bn |
| Mar 31, 2024 | 1.25 Bn |
| Dec 31, 2023 | 1.21 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.16 Bn |
| Dec 31, 2022 | 961.20 Mn |
| Sep 30, 2022 | 966.80 Mn |
| Jun 30, 2022 | 795.20 Mn |
| Mar 31, 2022 | 813.30 Mn |
| Dec 31, 2021 | 894.80 Mn |
| Sep 30, 2021 | 908.50 Mn |